Equity Overview
Price & Market Data
Price: $1.56
Daily Change: $0.00 / 0.00%
Daily Range: $1.47 - $1.87
Market Cap: $11,232,605
Daily Volume: 47,934
Performance Metrics
1 Week: 0.65%
1 Month: -18.32%
3 Months: -5.45%
6 Months: -40.91%
1 Year: -65.49%
YTD: -5.45%
Company Details
Employees: 12
Sector: Health technology
Industry: Biotechnology
Country: Israel
Details
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv-Yafo, Israel.